# AbbVie Inc. (ABBV) FY2024 Annual P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2024-01-01 to 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-14, accession number 0001551152-25-000020
- Page: https://plicit.ai/financials/abbv/fy2024-annual-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2024-annual-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2024-01-01 through 2024-12-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 56,334,000,000 US dollars
- **Cost of products sold**: 16,904,000,000 US dollars
- **Gross profit (calculated)**: 39,430,000,000 US dollars
- **Operating expenses (calculated)**: 30,293,000,000 US dollars
- **Operating earnings**: 9,137,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 5,421,000,000 US dollars
- **Earnings before income tax expense**: 3,716,000,000 US dollars
- **Income tax expense (benefit)**: negative 570,000,000 US dollars
- **Net earnings**: 4,286,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 2,720,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 1,177,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 1,279,000,000 US dollars
- **Eye Care - Alphagan/Combigan**: 248,000,000 US dollars
- **Eye Care - Lumigan/Ganfort**: 429,000,000 US dollars
- **Eye Care - Other Eye Care**: 847,000,000 US dollars
- **Eye Care - Ozurdex**: 494,000,000 US dollars
- **Eye Care - Restasis**: 224,000,000 US dollars
- **Oncology - Elahere**: 479,000,000 US dollars
- **Oncology - Epkinly**: 146,000,000 US dollars
- **Oncology - Imbruvica**: 3,347,000,000 US dollars
- **Oncology - Venclexta**: 2,583,000,000 US dollars
- **Immunology - Humira**: 8,993,000,000 US dollars
- **Immunology - Rinvoq**: 5,971,000,000 US dollars
- **Immunology - Skyrizi**: 11,718,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 3,283,000,000 US dollars
- **Neuroscience - Duodopa**: 447,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 338,000,000 US dollars
- **Neuroscience - Qulipta**: 658,000,000 US dollars
- **Neuroscience - Ubrelvy**: 1,006,000,000 US dollars
- **Neuroscience - Vraylar**: 3,267,000,000 US dollars
- **Other Key Products - Linzess/Constella**: 954,000,000 US dollars
- **Other Key Products - Mavyret**: 1,311,000,000 US dollars
- **Undisclosed (calculated)**: 4,415,000,000 US dollars
- **Selling, general and administrative**: 14,752,000,000 US dollars
- **Research and development**: 12,791,000,000 US dollars
- **Acquired IPR&D and milestones**: 2,757,000,000 US dollars
- **Other operating expense (income), net**: negative 7,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $4.28 B; to noncontrolling interests: $8.00 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/abbv/fy2024-annual-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/abbv-fy2024-annual-revenue-by-geography-sankey.png

Income statement for 2024-01-01 through 2024-12-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 56,334,000,000 US dollars
- **Cost of products sold**: 16,904,000,000 US dollars
- **Gross profit (calculated)**: 39,430,000,000 US dollars
- **Operating expenses (calculated)**: 30,293,000,000 US dollars
- **Operating earnings**: 9,137,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 5,421,000,000 US dollars
- **Earnings before income tax expense**: 3,716,000,000 US dollars
- **Income tax expense (benefit)**: negative 570,000,000 US dollars
- **Net earnings**: 4,286,000,000 US dollars
- **UNITED STATES**: 43,029,000,000 US dollars
- **GERMANY**: 1,465,000,000 US dollars
- **CANADA**: 1,088,000,000 US dollars
- **JAPAN**: 1,122,000,000 US dollars
- **CHINA**: 917,000,000 US dollars
- **FRANCE**: 776,000,000 US dollars
- **AUSTRALIA**: 463,000,000 US dollars
- **SPAIN**: 528,000,000 US dollars
- **UNITED KINGDOM**: 522,000,000 US dollars
- **ITALY**: 511,000,000 US dollars
- **BRAZIL**: 464,000,000 US dollars
- **All other countries**: 5,449,000,000 US dollars
- **Selling, general and administrative**: 14,752,000,000 US dollars
- **Research and development**: 12,791,000,000 US dollars
- **Acquired IPR&D and milestones**: 2,757,000,000 US dollars
- **Other operating expense (income), net**: negative 7,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $4.28 B; to noncontrolling interests: $8.00 M.